Relmada Therapeutics, Inc.

NasdaqGS:RLMD Stok Raporu

Piyasa değeri: US$102.6m

Relmada Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Relmada Therapeutics kazanç ve gelirinin sırasıyla yıllık 5.2% ve 75.4% oranında artması tahmin edilirken, EPS'nin yıllık 21.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

5.2%

Kazanç büyüme oranı

21.5%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi23.6%
Gelir büyüme oranı75.4%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme05 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

Mar 21

Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 13
Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark

Jan 14

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Dec 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Aug 29
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

May 07
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Dec 15
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure

Oct 14

Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up

Sep 14

Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression

Aug 09

We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Jul 14
We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Feb 26
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

4 Clinical Catalysts On Tap For Relmada In 2022

Jan 28

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Nov 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Our First Look At Relmada Therapeutics

Jun 28

We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Jun 28
We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 09
Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

Jan 15
What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017

Dec 07

Relmada Therapeutics (RLMD) Investor Presentation - Slideshow

Dec 02

Relmada Therapeutics (RLMD) Investor Presentation - Slideshow

Nov 16

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:RLMD - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202620-131-69N/A3
12/31/2025N/A-100-65N/A3
12/31/2024N/A-82-55N/A3
6/30/2024N/A-87-48-48N/A
3/31/2024N/A-94-48-48N/A
12/31/2023N/A-99-52-52N/A
9/30/2023N/A-112-77-77N/A
6/30/2023N/A-129-93-93N/A
3/31/2023N/A-144-101-101N/A
12/31/2022N/A-157-104-104N/A
9/30/2022N/A-153-106-106N/A
6/30/2022N/A-157-100-100N/A
3/31/2022N/A-143-95-95N/A
12/31/2021N/A-126-92-92N/A
9/30/2021N/A-112-61-61N/A
6/30/2021N/A-86-53-53N/A
3/31/2021N/A-71-40-40N/A
12/31/2020N/A-59-28-28N/A
9/30/2020N/A-43-25-25N/A
6/30/2020N/A-30-15-15N/A
3/31/2020N/A-23-14-14N/A
12/31/2019N/A-15-12-12N/A
9/30/2019N/A-18-11-11N/A
6/30/2019N/A-17-10-10N/A
3/31/2019N/A-17-9-9N/A
12/31/2018N/A-17-9-9N/A
9/30/2018N/A-11-7-7N/A
6/30/2018N/A-9-6-6N/A
3/31/2018N/A-7N/A-5N/A
12/31/2017N/A-6N/A-5N/A
9/30/2017N/A-6N/A-5N/A
6/30/2017N/A-6N/A-6N/A
3/31/2017N/A-8N/A-8N/A
12/31/2016N/A-8N/A-10N/A
9/30/2016N/A-9N/A-12N/A
6/30/2016N/A-3N/A-13N/A
3/31/2016N/A6N/A-15N/A
12/31/2015N/A6N/A-16N/A
9/30/2015N/A14N/A-17N/A
6/30/2015N/A-21N/A-16N/A
3/31/2015N/A-55N/A-13N/A
12/31/2014N/A-46N/A-9N/A
9/30/2014N/A-56N/A-5N/A
6/30/2014N/A-28N/A-3N/A
3/31/2014N/A-13N/A-3N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RLMD önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: RLMD önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: RLMD önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: RLMD gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: RLMD gelecek yıl gelir elde edemeyeceği tahmin ediliyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RLMD 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok


Büyüyen şirketleri keşfedin